Key Points Merck is seeking ways to prepare for a significant upcoming patent cliff.The company has just announced another ...

From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...

Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...

US Foods Holding stock hit an all-time high Friday on a report that the firm was mulling an acquisition of Performance Food ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

U.S. appetite for U.K. companies is only intestifying in 2025; here, Law.com charts some of the highest profile deals in H1, ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

On this week's episode of "The Readout LOUD": a closer look at the NIH’s grant-cutting legal playbook, FDA transparency ...